AP9901720A0 - Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. - Google Patents

Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.

Info

Publication number
AP9901720A0
AP9901720A0 APAP/P/1999/001720A AP9901720A AP9901720A0 AP 9901720 A0 AP9901720 A0 AP 9901720A0 AP 9901720 A AP9901720 A AP 9901720A AP 9901720 A0 AP9901720 A0 AP 9901720A0
Authority
AP
ARIPO
Prior art keywords
alpha
treatment
diabetes
thiazolidinedione
glucosidase inhibitors
Prior art date
Application number
APAP/P/1999/001720A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AP9901720A0 publication Critical patent/AP9901720A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
APAP/P/1999/001720A 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors. AP9901720A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003691 WO1998057635A1 (fr) 1997-06-18 1998-06-15 Traitement du diabete a l'aide de thiazolidinedione et d'un inhibiteur des alpha-glucosidases

Publications (1)

Publication Number Publication Date
AP9901720A0 true AP9901720A0 (en) 1999-12-31

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001720A AP9901720A0 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.

Country Status (24)

Country Link
EP (1) EP0975343A1 (fr)
JP (1) JP2001523271A (fr)
KR (1) KR20010013845A (fr)
CN (1) CN1274282A (fr)
AP (1) AP9901720A0 (fr)
AR (2) AR013352A1 (fr)
AU (1) AU8799998A (fr)
BG (1) BG103966A (fr)
BR (1) BR9810186A (fr)
CA (1) CA2294134A1 (fr)
CO (1) CO4940453A1 (fr)
DZ (1) DZ2519A1 (fr)
EA (1) EA200000040A1 (fr)
IL (1) IL133138A0 (fr)
MA (1) MA26510A1 (fr)
NO (1) NO996270D0 (fr)
NZ (1) NZ501345A (fr)
OA (1) OA11631A (fr)
PE (1) PE89199A1 (fr)
PL (1) PL337577A1 (fr)
SK (1) SK179499A3 (fr)
TR (1) TR199903072T2 (fr)
UY (1) UY25051A1 (fr)
WO (1) WO1998057635A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL351686A1 (en) 1999-04-23 2003-06-02 Smithkline Beecham Plc Novel pharmaceutical
WO2002080936A1 (fr) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Polytherapie comprenant des inhibiteurs de reabsorption du glucose et des modulateurs ppar
DE60233655D1 (de) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R und retinoid x rezeptorenmodulatoren
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
NZ501345A (en) 2001-10-26
UY25051A1 (es) 2000-09-29
NO996270L (no) 1999-12-17
DZ2519A1 (fr) 2003-02-01
AR014881A1 (es) 2001-04-11
TR199903072T2 (xx) 2000-07-21
OA11631A (en) 2004-11-22
KR20010013845A (ko) 2001-02-26
CO4940453A1 (es) 2000-07-24
AR013352A1 (es) 2000-12-27
NO996270D0 (no) 1999-12-17
BG103966A (bg) 2000-07-31
BR9810186A (pt) 2000-08-08
MA26510A1 (fr) 2004-12-20
SK179499A3 (en) 2000-11-07
EA200000040A1 (ru) 2000-08-28
CA2294134A1 (fr) 1998-12-23
EP0975343A1 (fr) 2000-02-02
IL133138A0 (en) 2001-03-19
WO1998057635A1 (fr) 1998-12-23
JP2001523271A (ja) 2001-11-20
PE89199A1 (es) 1999-10-23
CN1274282A (zh) 2000-11-22
PL337577A1 (en) 2000-08-28
AU8799998A (en) 1999-01-04

Similar Documents

Publication Publication Date Title
AP2002002703A0 (en) Combinations of depeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diadetes mellitus.
EP1787646A3 (fr) Nouveau procédé de traitement
WO2000062766A3 (fr) Nouveau procede de traitement
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
TR199903095T2 (xx) Diabetin roziglitazon ve ins�lin ile tedavisi.
AP2000001735A0 (en) Treatment of diabetes with thiazolidinedione insulin secretagogue and alpha glucocidase inhibitor.
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
TR200101336T2 (tr) Bir-beta-agonisti ile başka bir antidiyabetik madde içeren kombinasyonlar
WO2001047509A3 (fr) Procede de traitement
NZ503862A (en) Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia
HUP0002569A2 (hu) Diabetes kezelésére alkalmas dioxo-tiazolidint és alfa-glükozidáz inhibitort tartalmazó gyógyszerkészítmények
ECSP982541A (es) Nuevo metodo de tratamiento ii
YU28700A (sh) Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije
PL327472A1 (en) Nitrogen oxide (no) synthase inhibitor for use in treatment or polphylaxy of type ii diabetes
MY118982A (en) Method of reducing tissue damage associated with ischemia
ECSP982542A (es) Nuevo metodo de tratamiento iii
ECSP982593A (es) Nuevo metodo de tratamiento vi
MX9701533A (es) Procedimiento para reducir lesiones en tejidos asociadas con isquemia no cardiaca.